Aluminum and Alzheimer's disease: After a century of controversy, is there a plausible link?

Journal of Alzheimer's Disease

Volumn 23, Issue 4, 2011, Pages 567-598

  Tomljenovic, Lucija ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Aging; aluminum; Alzheimer's disease; amyloidosis; bioavailability; brain compartmentalization; cholinergic dysfunction; G proteins; neurofibrillary tangles; neurotoxicity

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM; ANTACID AGENT; ANTIDIARRHEAL AGENT; ANTIULCER AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; IRON;

AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; BLOOD BRAIN BARRIER; BRAIN REGION; CALCIUM HOMEOSTASIS; CARBONATED BEVERAGE; CELL LOSS; CHROMATIN STRUCTURE; COGNITION; DIALYSIS ENCEPHALOPATHY; DIETARY INTAKE; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; LIPID PEROXIDATION; MEMORY; NERVE CELL; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; REVIEW; SIGNAL TRANSDUCTION;

EID: 79953280497     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101494     Document Type: Review

References (317)

1. Thomas P, Fenech M (2007) A review of genome mutation and Alzheimer's disease. Mutagenesis 22, 15-33. (Pubitemid 46058638)
2. Walton JR (2009) Brain lesions comprised of aluminumrich cells that lack microtubules may be associated with the cognitive deficit of Alzheimer's disease. Neurotoxicology 30, 1059-1069.
3. Thathiah A, De Strooper B (2009) G protein-coupled receptors, cholinergic dysfunction, and Abeta toxicity in Alzheimer's disease. Sci Signal 2, re8.
4. Garcia-Jimenez A, Cowburn RF, Ohm TG, Lasn H, Winblad B, Bogdanovic N, Fastbom J (2002) Loss of stimulatory effect of guanosine triphosphate on [(35)S]GTPgammaS binding correlates with Alzheimer's disease neurofibrillary pathology in entorhinal cortex and CA1 hippocampal subfield. J Neurosci Res 67, 388-398. (Pubitemid 34137146)
5. Cowburn RF, O'Neill C, Bonkale WL, Ohm TG, Fastbom J (2001) Receptor-G-protein signalling in Alzheimer's disease. Biochem Soc Symp 67, 163-175. (Pubitemid 33602684)
6. Exley C (1999) A molecular mechanism of aluminiuminduced Alzheimer's disease? J Inorg Biochem 76,133-140.
7. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR (1999) Alzheimer neuropathologic alterations in aged cog-nitively normal subjects. J Neuropathol Exp Neurol 58, 376-388. (Pubitemid 29187900)
8. Greenwood AF, Powers RE, Jope RS (1995) Phosphoinositide hydrolysis, G alpha q, phospholipase C, and protein kinaseCinpostmortemhumanbrain: effectsofpostmortem interval, subject age, and Alzheimer's disease. Neuroscience 69, 125-138.
9. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL (1984) Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225, 1168-1170. (Pubitemid 14029099)
10. Bertholf RL (1987) Aluminum and Alzheimer's disease: perspectives for a cytoskeletal mechanism. Crit Rev Clin Lab Sci 25, 195-210.
11. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117. (Pubitemid 41797645)
12. LaFerla FM (2002) Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 3, 862-872.
13. Annaert W, Cupers P, Saftig P, De Strooper B (2000) Presenilin function in APP processing. Ann N Y Acad Sci 920, 158-164. (Pubitemid 32056564)
14. Drago D, Bolognin S, Zatta P (2008) Role of metal ions in the abeta oligomerization in Alzheimer's disease and in other neurological disorders. Curr Alzheimer Res 5, 500-507.
15. Miu AC, Benga O (2006) Aluminum and Alzheimer's disease: a new look. J Alzheimers Dis 10, 179-201. (Pubitemid 44767493)
16. Lukiw WJ, Bazan NG (2000) Neuroinflammatory signaling upregulation in Alzheimer's disease. Neurochem Res 25, 1173-1184.
17. Pratico D, Delanty N (2000) Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J Med 109, 577-585.
18. Walton JR (1996) Amyloid, aluminium and the aetiology of Alzheimer's disease. Med J Aust 164, 382-383.
19. Joshi JG, Dhar M, Clauberg M, Chauthaiwale V (1994) Iron and aluminum homeostasis in neural disorders. Environ Health Perspect 102(Suppl 3), 207-213. (Pubitemid 24316384)
20. MatsuyamaSS, JarvikLF (1989) Hypothesis: microtubules, a key to Alzheimer disease. Proc Natl Acad Sci USA 86, 8152-8156. (Pubitemid 19265337)
21. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amy-loidosis. J Neurosci 21, 4183-4187. (Pubitemid 32538543)
22. Buxbaum JD, Ruefli AA, Parker CA, Cypess AM, Greengard P (1994) Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc Natl Acad Sci US A 91, 4489-4493. (Pubitemid 24143459)
23. Kurumatani T, Fastbom J, Bonkale WL, Bogdanovic N, Winblad B, Ohm TG, Cowburn RF (1998) Loss of inositol 1,4,5-trisphosphate receptor sites and decreased PKC levels correlate with staging of Alzheimer's disease neurofibrillary pathology. Brain Res 796, 209-221.
24. Thompson K, Menzies S, Muckenthaler M, Torti FM, Wood T, Torti SV, Hentze MW, Beard J, Connor J (2003) Mouse brains deficient in H-ferritin have normal iron concentra-tion but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res 71, 46-63. (Pubitemid 36008401)
25. Connor JR, Menzies SL, St Martin SM, Mufson EJ (1992) A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 31, 75-83.
26. Kell DB (2009) Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vas-cular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2, 2.
27. Yokel RA (2006) Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. J Alzheimers Dis 10, 223-253. (Pubitemid 44763995)
28. Lumbreras M, Baamonde C, Martinez-Cue C, Lubec G, Cairns N, Salles J, Dierssen M, Florez J (2006) Brain G protein-dependent signaling pathways in Down syndrome and Alzheimer's disease. Amino Acids 31, 449-456. (Pubitemid 44853466)
29. Pratico D, Trojanowski JQ (2000) Inflammatory hypothe-ses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets? Neurobiol Aging 21, 441-445; discussion 451-443. (Pubitemid 30349112)
30. Nee LE, Eldridge R, Sunderland T, Thomas CB, Katz D, Thompson KE, Weingartner H, Weiss H, Julian C, Cohen R (1987) Dementia of the Alzheimer type: clinical and family study of 22 twin pairs. Neurology 37, 359-363. (Pubitemid 17031728)
31. Gupta VB, Anitha S, Hegde ML, Zecca L, Garruto RM, Ravid R, Shankar SK, Stein R, Shanmugavelu P, Jagannatha Rao KS (2005) Aluminium in Alzheimer's disease: are we still at a crossroad? Cell Mol Life Sci 62, 143-158. (Pubitemid 40193039)
32. Exley C (2001) Aluminium and Alzheimer's Disease: The Science that Describes the Link, Elsevier Science, Amsterdam, p. 452.
33. Moore PB, Day JP, Taylor GA, Ferrier IN, Fifield LK, Edwardson JA (2000) Absorption of aluminium-26 in Alzheimer's disease, measured using accelerator mass spec-trometry. Dement Geriatr Cogn Disord 11, 66-69. (Pubitemid 30114086)
34. Savory J, Exley C, Forbes WF, Huang Y, Joshi JG, Kruck T, McLachlan DR, Wakayama I (1996) Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered? J Toxicol Environ Health 48, 615-635.
35. Forbes WF, Hill GB (1998) Is exposure to aluminum a risk factor for the development of Alzheimer disease?-Yes. Arch Neurol 55, 740-741. (Pubitemid 28224309)
36. Munoz DG (1998)Is exposuretoaluminumariskfactorfor the development of Alzheimer disease?-No. Arch Neurol 55, 737-739.
37. Exley C, Korchazhkina O, Job D, Strekopytov S, Polwart A, Crome P (2006) Non-invasive therapy to reduce the body burden of aluminium in Alzheimer's disease. J Alzheimers Dis 10, 17-24; discussion 29-31. (Pubitemid 44401360)
38. ATSDR (2008) Toxicological profile for aluminum. Agency for toxic substances and disease registry, Atlanta, GA, p. 357, http://www.atsdr.cdc.gov/ toxprofiles/tp22.html, Last Updated August 7, Accessed on July 4 2010.
39. Carson (2000) Aluminum Compounds. Review of Toxicological Literature, Abridged Final Report, Integrated Laboratory Systems, Research Triangle Park, NC, p. 84, http://ntp.niehs.nih.gov/ntp/htdocs/Chem-Background/ExSumpdf/ Aluminum.pdf, Accessed on July 2010.
40. Priest ND (1993) Satellite symposium on Alzheimer's dis-ease and dietary aluminium. ProcNutr Soc 52, 231-240.
41. McDermott JR, Smith AI, Iqbal K, Wisniewski HM (1979) Brain aluminum in aging and Alzheimer disease. Neurology 29, 809-814. (Pubitemid 9160981)
42. Perl DP, Brody AR (1980) Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neu-rofibrillary tangle-bearing neurons. Science 208, 297-299. (Pubitemid 10075227)
43. Kowall NW, Pendlebury WW, Kessler JB, Perl DP, Beal MF (1989) Aluminum-induced neurofibrillary degenera-tion affects a subset of neurons in rabbit cerebral cortex, basal forebrain and upper brainstem. Neuroscience 29, 329-337. (Pubitemid 19113424)
44. Edwardson JA, Candy JM, Ince PG, McArthur FK, Morris CM, Oakley AE, Taylor GA, Bjertness E (1992) Aluminium accumulation, beta-amyloid deposition and neurofibrillary changes in the central nervous system. Ciba Found Symp 169, 165-179; discussion 179-185.
45. Harrington CR, Wischik CM, McArthur FK, Taylor GA, Edwardson JA, Candy JM (1994) Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet 343, 993-997. (Pubitemid 24122606)
46. Perl DP, Moalem S (2006) Aluminum and Alzheimer's dis-ease, apersonal perspective after 25 years. J Alzheimers Dis 9, 291-300. (Pubitemid 44253322)
47. Walton JR (2006) Aluminum in hippocampal neurons from humans with Alzheimer's disease. Neurotoxicology 27,385-394.
48. Walton JR (2009) Functional impairment in aged rats chronically exposed to human range dietary aluminum equivalents. Neurotoxicology 30, 182-193.
49. McLachlan DRC, Krishnan SS, Dalton AJ (1973) Brain aluminum distribution in Alzheimer's disease and experimental neurofibrillary degeneration. Science 180, 511-513.
50. Matyja E (2000) Aluminum enhances glutamate-mediated neurotoxicity in organotypic cultures of rat hippocampus. Folia Neuropathol 38, 47-53. (Pubitemid 36050159)
51. Andrasi E, Pali N, Molnar Z, Kosel S (2005) Brain aluminum, magnesium and phosphorus contents of control and Alzheimer-diseased patients. J Alzheimers Dis 7, 273-284. (Pubitemid 41206938)
52. Uemura E (1984) Intranuclear aluminum accumulation in chronic animals with experimental neurofibrillary changes. Exp Neurol 85, 10-18. (Pubitemid 14088942)
53. Chafi AH, Hauw JJ, Rancurel G, Berry JP, Galle C (1991) Absence of aluminium in Alzheimer's disease brain tissue: electron microprobe and ion microprobe studies. Neurosci Lett 123, 61-64.
54. Landsberg JP, McDonald B, Watt F (1992) Absence of aluminium in neuritic plaque cores in Alzheimer's disease. Nature 360, 65-68.
55. Priest ND, Talbot RJ, Newton D, Day JP, King SJ, Fifield LK (1998) Uptake by man of aluminium in a public water supply. Hum Exp Toxicol 17, 296-301. (Pubitemid 28342336)
56. Gupta DM (2003) Renal osteodystrophy and aluminium bone disease in patients with chronic renal failure. JK Practitioner 10, 107-111.
57. Wills MR, Savory J (1985) Water content of aluminum, dial-ysis dementia, and osteomalacia. Environ Health Perspect 63, 141-147. (Pubitemid 16179344)
58. Shore D, Wyatt RJ (1983) Aluminum and Alzheimer's disease. J Nerv Ment Dis 171, 553-558. (Pubitemid 13004493)
59. McLachlan DRC, Quittkat S, Krishnan SS, Dalton AJ, De Boni U (1980) Intranuclear aluminum content in Alzheimer's disease, dialysis encephalopathy, and exper-imental aluminum encephalopathy. Acta Neuropathol 50, 19-24. (Pubitemid 10148209)
60. McLachlan DRC, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF (1991) Intramuscular desfer-rioxamine in patients with Alzheimer's disease. Lancet 337, 1304-1308.
61. Walton JR (2007) A longitudinal study of rats chronically exposed to aluminum at human dietary levels. Neurosci Lett 412, 29-33. (Pubitemid 46038549)
62. Klaasen CD (1996) Heavy metals and heavy metal antago-nists. In Goodman & Gilson's The Pharmacological Basis of Therapeutics, Hardman JG, LimbirdLE, eds, McGraw-Hill, New York, pp. 1649-1672.
63. Yokel RA, Allen DD, Meyer JJ (1994) Studies of aluminum neurobehavioral toxicity in the intact mammal. Cell Mol Neurobiol 14, 791-808.
64. 3+ on rat brain synaptosomal uptake of noradrenaline and serotonin. J Inorg Biochem 17, 215-225. (Pubitemid 13015539)
65. Lukiw WJ, Kruck TP, McLachlan DR (1987) Alterations in human linker histone-DNA binding in the presence of aluminum salts in vitro and in Alzheimer's disease. Neurotoxicology 8, 291-301. (Pubitemid 17098976)
66. Landsberg J, McDonald B, Grime G, Watt F (1993) Microanalysis of senile plaques using nuclear microscopy. J Geriatr Psychiatry Neurol 6, 97-104. (Pubitemid 23183396)
67. Walton J, Tuniz C, Fink D, Jacobsen G, Wilcox D (1995) Uptake of trace amounts of aluminum into the brain from drinking water. Neurotoxicology 16, 187-190.
68. Yokel RA (2002) Brain uptake, retention, and efflux of aluminum and manganese. Environ Health Perspect 110 (Suppl. 5), 699-704. (Pubitemid 35276852)
69. King SJ, Oldham C, Popplewell JF, Carling RS, Day JP, Fifield LK, Cresswell RG, Liu K, di Tada ML (1997) Determination of aluminium-26 in biological materials by accelerator mass spectrometry. Analyst 122, 1049-1055. (Pubitemid 27474844)
70. Walton JR, Wang MX (2009) APP expression, distribution and accumulation are altered by aluminum in a rodent model for Alzheimer's disease. J Inorg Biochem 103, 1548-1554.
71. WHO (1998) Aluminium in Drinking-water. Background document for development of WHO Guidelines for drinking-water quality. In Guidelines for Drinking-Water Quality, 2nd ed., Addendum to Vol. 2. Health Health Criteria and Other Supporting Information, Geneva, p. 14, http://www.who.int/ water&sanitation-health/dwq/chemicals/en/aluminium.pdf, Accessed on July 4 2010.
72. Barabasz W, Albińska D, Jaśkowska M, Lipiec J (2002) Ecotoxicology of Aluminium. Pol J Env Stud 11, 199-203. (Pubitemid 135707283)
73. Miller RG, Kopfler FC, Kelty KC, Stober JA, Ulmer NS (1984) The occurrence of aluminum in drinking water. JAm Water Works Assoc 76, 84-91.
74. Plunkert PA (1998) Aluminum. Annual average pri-mary aluminum price. USMB, 1-4, http://minerals.usgs.gov/minerals/pubs/commodity/aluminum/050798.pdf
75. Zhang P, McCormick M, Hughes J (1994) Behaviour of aluminium during water treatment. In Research report No. 85, Melbourne: Urban Water Research Association of Australia, Melbourne, p. 135.
76. Shovlin MG, Yoo RS, Crapper-McLachlan DR, Cummings E, Donohue JM, Hallman WK, Khachaturian Z, OrmeZavaleta J, Teefy S (1993) Aluminium in drinking water and Alzheimer's disease; a resource guide. In AWWA Research Foundation and the American Water Works Association, Denver, CO, pp. 7-8.
77. Strunecka A, Strunecky O, Patocka J (2002) Fluoride plus aluminum: useful tools in laboratory investigations, but messengers of false information. Physiol Res 51, 557-564. (Pubitemid 36168662)
78. Strunecka A, Patocka J, Blaylock RL, Chinoy NJ (2007) Flu-oride interactions: from molecules to diseases. Curr Signal Transduct Ther 2, 190-213.
79. Strunecka A, Patocka J (2002) Aluminofluoride complexes: A Useful Tool in Laboratory Investigations, but a Hidden DangerforLiving Organisms? ACS Symposium Series, 822, American Chemical Society, pp. 271-282. (Pubitemid 135715531)
80. Chen Y, Penington NJ (2000) Competition between internal AlF4-Stimulation of dorsal raphe neuron G-proteins coupled to calcium current inhibition. J Neurophysiology 83, 1273-1282. (Pubitemid 30159556)
81. Bigay J, Deterre P, Pfister C, Chabre M (1987) Fluoride complexes of aluminium or beryllium act on G-proteins as reversibly bound analogues of the gamma phosphate of GTP. EMBO J 6, 2907-2913.
82. Varner JA, Jensen KF, Horvath W, Isaacson RL (1998) Chronic administration of aluminum-fluoride or sodium-fluoride to rats in drinking water: alterations in neuronal and cerebrovascular integrity. Brain Res 784, 284-298. (Pubitemid 28137871)
83. Varner JA, Horvath WJ, Huie CW, Naslund HR, Isaacson RL (1994) Chronic aluminum fluoride administration. I. Behavioral observations. Behav Neural Biol 61, 233-241.
84. Ziegelbecker F (1998) Fluoridation in Europe. Fluoride 31, 171-174.
85. Alzheimer A (1907) Ueber einen eigenartige Erkrankung der Hirnrinde. Zentralblatt fur Nervenheilkunde und Psychiatrie 30, 177-179.
86. James GWB (1926) The treatment of senile insanity. Lancet 2, 820-821.
87. Shaw CA, Petrik MS (2009) Aluminum hydroxide injec-tions lead to motor deficits and motor neuron degeneration. J Inorg Biochem 103, 1555-1562.
88. Yokel RA, Hicks CL, Florence RL (2008) Aluminum bioavailability from basic sodium aluminum phosphate, an approved food additive emulsifying agent, incorporated in cheese. Food Chem Toxicol 46, 2261-2266.
89. Saiyed SM, Yokel RA (2005) Aluminium content of some foods and food products in the USA, with aluminium food additives. Food Addit Contam 22, 234-244. (Pubitemid 40778722)
90. Lopez FE, Cabrera C, Lorenzo ML, Lopez MC (2002) Aluminum levels in convenience and fast foods: in vitro study of the absorbable fraction. Sci Total Environ 300, 69-79. (Pubitemid 35430170)
91. Rogers MA, Simon DG (1999) A preliminary study of dietary aluminium intake and risk of Alzheimer's disease. Age Ageing 28, 205-209. (Pubitemid 29161228)
92. Exley C (1998) Does antiperspirant use increase the risk of aluminium-related disease, including Alzheimer's disease? Mol Med Today 4, 107-109. (Pubitemid 28155128)
93. Greger JL, Sutherland JE (1997) Aluminum exposure and metabolism. Crit Rev Clin Lab Sci 34, 439-474. (Pubitemid 27514230)
94. Pennington JA, Schoen SA (1995) Estimates of dietary exposure to aluminium. Food Addit Contam 12, 119-128.
95. Dabeka RW, McKenzie AD (1990) Aluminium levels in Canadian infant formulate and estimation of aluminium intakes from formulae by infants 0-3 months old. Food Addit Contam 7, 275-282. (Pubitemid 20206139)
96. Gitelman HJ (1989) Aluminum and Health: a Critical Review, Dekker, New York.
97. Pennington JA (1988) Aluminium content of foods and diets. Food Addit Contam 5, 161-232. (Pubitemid 18062489)
98. Gies WJ (1911) Some objections to the use of alum baking-powder. JAMA 57, 816-821.
99. Flaten TP (1990) Geographical associations between Aluminum in drinking water and death rates with dementia (including Alzheimer's disease), Parkinson's disease and amyotrophic lateral sclerosis in Norway. Environ Geochem Health 12, 152-167.
100. McLachlan DRC, Bergeron C, Smith JE, Boomer D, Rifat SL (1996) Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. Neurology 46, 401-405. (Pubitemid 26081321)
101. Rondeau V, Commenges D, Jacqmin-Gadda H, Dartigues JF (2000) Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study. Am J Epidemiol 152, 59-66. (Pubitemid 30637398)
102. Rondeau V, Jacqmin-Gadda H, Commenges D, Helmer C, Dartigues JF (2009) Aluminum and silica in drinking water and the risk of Alzheimer's disease or cognitive decline: findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol 169, 489-496.
103. Martyn CN, Barker DJ, Osmond C, Harris EC, Edwardson JA, Lacey RF (1989) Geographical relation between Alzheimer's disease and aluminum in drinking water. Lancet1, 59-62. (Pubitemid 19033991)
104. Jacqmin-Gadda H, Commenges D, Letenneur L, Dartigues JF (1996) Silica and aluminum in drinking water and cog-nitive impairment in the elderly. Epidemiology 7, 281-285. (Pubitemid 26120375)
105. Neri LC, Hewitt D (1991) Aluminium, Alzheimer's disease, and drinking water. Lancet 338, 390.
106. Gillette-Guyonnet S, Andrieu S, Nourhashemi F, de La Gueronniere V, Grandjean H, Vellas B (2005) Cognitive impairment and composition of drinking water in women: findings of theEPIDOS Study. Am J Clin Nutr 81, 897-902. (Pubitemid 41725000)
107. Campbell A, Becaria A, Lahiri DK, Sharman K, Bondy SC (2004) Chronic exposure to aluminum in drinking water increases inflammatory parameters selectively in the brain. J Neurosci Res 75, 565-572. (Pubitemid 38160717)
108. Flaten TP (2001) Aluminium as a risk factor in Alzheimer's disease, with emphasis on drinking water. Brain Res Bull 55, 187-196. (Pubitemid 32722158)
109. Greger JL (1993) Aluminum metabolism. Annu Rev Nutr 13, 43-63. (Pubitemid 23227776)
110. FAO/WHO (2006) Summary and conclusions of the sixty-seventh meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), Sixty-seventh meeting in Rome, 20-29 June 2006, p. 11, http://www.who.int/ipcs/food/jecfa/ jecfa67-call%20final.pdf, Issued July 7 2006, Accessed on July 2010.
111. Zheng W (2001) Neurotoxicology of the brain barrier sys-tem: new implications. J Toxicol Clin Toxicol 39, 711-719. (Pubitemid 34016566)
112. Poole RL, Hintz SR, Mackenzie NI, Kerner JA Jr (2008) Aluminum exposure from pediatric parenteral nutrition: meeting the new FDA regulation. J Parenter Enteral Nutr 32, 242-246.
113. Newschaffer CJ, Croen LA, Daniels J, Giarelli E, Grether JK, Levy SE, Mandell DS, Miller LA, Pinto-Martin J, Reaven J, Reynolds AM, Rice CE, Schendel D, Windham GC (2007) The epidemiology of autism spectrum disorders. Annu Rev Public Health 28, 235-258. (Pubitemid 46833342)
114. Kogan MD, Blumberg SJ, Schieve LA, Boyle CA, Perrin JM, Ghandour RM, Singh GK, Strickland BB, Trevathan E, van DyckPC (2009) Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 124, 1395-1403.
115. Baron-Cohen S, Scott FJ, Allison C, Williams J, Bolton P, Matthews FE, Brayne C (2009) Prevalence of autism-spectrum conditions: UK school-based population study. Br J Psychiatry 194, 500-509.
116. Offit PA, Jew RK (2003) Addressing parents' concerns: do vaccines containharmfulpreservatives, adjuvants, additives, or residuals? Pediatrics 112, 1394-1397.
117. Flarend RE, Hem SL, White JL, Elmore D, Suckow MA, Rudy AC, Dandashli EA (1997) In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine 15, 1314-1318. (Pubitemid 27397805)
118. Yokel RA, McNamara PJ (2001) Aluminiumtoxicokinetics: an updated minireview. Pharmacol Toxicol 88, 159-167.
119. Glaxo Smith Kline (2009) Boostrix product monograph, Combined diphtheria, tetanus, acellularpertussis (adsorbed) vaccine for booster vaccination, Date of Approval: October 21, 2009 http://www.gsk.ca/english/docs-pdf/Boostrix-PM- 20091021-EN.pdf, Accessed on August 4, 2010.
120. Makidon PE, Bielinska AU, Nigavekar SS, Janczak KW, Knowlton J, Scott AJ, Mank N, Cao Z, Rathinavelu S, Beer MR, Wilkinson JE, Blanco LP, Landers JJ, Baker JR Jr (2008) Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One 3, e2954.
121. Exley C (2009) Aluminium and medicine. In Molecular and Supramolecular Bioinorganic Chemistry: Applications in Medical Sciences, Merce ALR, Felcman J, Recio MAL, eds, Nova Biomedical Books, New York, pp. 45-68.
122. Blaylock RL (2004) Excitotoxicity: apossible central Mechanism in fluoride neurotoxicity. Fluoride 37, 264-277.
123. Gherardi RK (2003) Lessons from macrophagic myofasci-itis: towards definition of a vaccine adjuvant-related syndrome. Rev Neurol (Paris) 159, 162-164. (Pubitemid 36292557)
124. Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, Pellissier JF, Chariot P, Authier FJ (2001) Macrophagic myofasciitis lesions assess long-term persis-tence of vaccine-derived aluminium hydroxide in muscle. Brain 124, 1821-1831. (Pubitemid 32845443)
125. Authier FJ, Cherin P, Creange A, Bonnotte B, Ferrer X, Abdelmoumni A, Ranoux D, Pelletier J, Figarella-Branger D, Granel B, Maisonobe T, Coquet M, Degos JD, Gherardi RK (2001) Central nervous system disease in patients with macrophagic myofasciitis. Brain 124, 974-983. (Pubitemid 32458509)
126. Exley C, Swarbrick L, Gherardi RK, Authier FJ (2009) A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med Hypotheses 72, 135-139.
127. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Adjuvants and autoimmunity. Lupus 18, 1217-1225.
128. Shoenfeld Y, Agmon-Levin N (2010) 'ASIA'-Autoim-mune/inflammatory syndrome induced by adjuvants. J Autoimmun, [Epub ahead of print] doi:10.1016/j.jaut.2010.07.003.
129. Petrik MS, Wong MC, Tabata RC, Garry RF, Shaw CA (2007) Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice. Neuromolecular Med 9, 83-100. (Pubitemid 44772277)
130. Pennington JA, Jones JW (1989) Dietary intake of aluminum In A luminum and health: a critical review, Gitelman HJ, ed., Dekker, New York, pp. 67-101.
131. Xiong JS, Branigan D, Li M (2009) Deciphering the MSG controversy. Int J Clinical Exp Med 2, 329-336.
132. Gonzalez-Burgos I, Velazquez-Zamora DA, Beas-Zarate C (2009) Damage and plasticity in adult rat hippocampal trisynaptic circuit neurons after neonatal exposure to glu-tamate excitotoxicity. Int J Dev Neurosci 27, 741-745.
133. Deloncle R, Fauconneau B, Piriou A, Huguet F, Guillard O (2002) Aluminum L-glutamate complex in rat brain cor-tex: in vivo prevention of aluminum deposit by magnesium D-aspartate. Brain Res 946, 247-252. (Pubitemid 34876337)
134. Deloncle R, Guillard O, Huguet F, Clanet F (1995) Modifica-tion of the blood-brain barrier through chronic intoxication by aluminum glutamate. Possible role in the etiology of Alzheimer's disease. Biol Trace Elem Res 47, 227-233.
135. Nayak P, Chatterjee AK (2003) Dietary protein restric-tion causes modification in aluminum-induced alteration in glutamate and GABA system of rat brain. BMC Neurosci 4, 4.
136. Cunat L, Lanhers MC, Joyeux M, BurnelD (2000) Bioavail-ability and intestinal absorption of aluminum in rats: effects of aluminum compounds and some dietary constituents. Biol Trace Elem Res 76, 31-55. (Pubitemid 30624271)
137. Mundy WR, Freudenrich TM, Kodavanti PR (1997) Aluminum potentiates glutamate-induced calcium accu-mulation and iron-induced oxygen free radical formation in primary neuronal cultures. Mol Chem Neuropathol 32, 41-57.
138. Sorenson JR, Campbell IR, Tepper LB, Lingg RD (1974) Aluminum in the environment and human health. Environ Health Perspect 8, 3-95.
139. Exley C (2004) Aluminuminantiperspirants: morethanjust skin deep. Am J Med 117, 969-970.
140. Guillard O, Fauconneau B, Olichon D, Dedieu G, Deloncle R (2004) Hyperaluminemia in a woman using an aluminum-containing antiperspirant for 4 years. Am J Med 117, 956-959. (Pubitemid 40075565)
141. Graves AB, White E, Koepsell TD, Reifler BV, van Belle G, Larson EB (1990) The association between aluminum-containing products and Alzheimer's disease. J Clin Epidemiol 43, 35-44. (Pubitemid 20036963)
142. FDA DHHS (2003) Skin Protectant Drug Products for Over-the-Counter Human Use, Final Monograph. Fed Regist 68, 34273-34290.
143. Alzheimer Society of Canada, Alzheimer's Disease, Causes of Alzheimer's Disease, http://www.alzheimer.ca/english/disease/causes-alumi.htm, Last updated March 2009, Accessed on August 4, 2010.
144. Polizzi S, Pira E, Ferrara M, Bugiani M, Papaleo A, Albera R, Palmi S (2002) Neurotoxic effects of aluminium among foundry workers and Alzheimer's disease. Neurotoxicology 23, 761-774. (Pubitemid 36004742)
145. Sinczuk-Walczak H, Szymczak M, Razniewska G, Matczak W, Szymczak W (2003) Effects of occupational exposure to aluminum on nervous system: clinical and electroen-cephalographic findings. Int J Occup Med Environ Health 16, 301-310. (Pubitemid 38141866)
146. Joshi JG (1991) Neurochemical hypothesis: participation by aluminum in producing critical mass of colocalized errors in brain leads to neurological disease. Comp Biochem Physiol C100, 103-105.
147. Shafer TJ, Mundy WR (1995) Effects of aluminum on neuronal signal transduction: mechanisms underlying disruption of phosphoinositide hydrolysis. Gen Pharmacol 26, 889-895.
148. Mundy WR, Kodavanti PR, Dulchinos VF, Tilson HA (1994) Aluminum alters calcium transport in plasma mem-brane and endoplasmic reticulum from rat brain. J Biochem Toxico 19, 17-23.
149. Macdonald TL, Humphreys WG, Martin RB (1987) Promotion of tubulin assembly by aluminum ion in vitro. Science 236, 183-186. (Pubitemid 17061035)
150. McLachlan DRC, Farnell BJ (1986) Cellular mechanisms of aluminium toxicity. Ann Ist Super Sanita 22, 697-702. (Pubitemid 16098587)
151. Siegel N, Haug A (1983) Aluminum interaction with calmodulin. Evidence for altered structure and function from optical and enzymatic studies. Biochim Biophys Acta 744, 36-45. (Pubitemid 13101040)
152. Roskams AJ, Connor JR (1990) Aluminum access to the brain: a role for transferrin and its receptor. Proc Natl Acad Sci USA 87, 9024-9027. (Pubitemid 120007642)
153. +)ATPase. Toxicol Sci 88, 485-494. (Pubitemid 41672156)
154. Exley C, Price NC, Birchall JD (1994) Aluminum inhibition of hexokinase activity in vitro: a study in biological availability. J Inorg Biochem 54, 297-304. (Pubitemid 24164578)
155. Lukiw WJ (2001) Aluminum and gene transcription in the mammalian central nervous system-implications for Alzheimer's Disease. In A luminium and Alzheimer's Disease: The science that describes the link, Exley C, ed., Elsevier Science, Amsterdam, pp. 147-169.
156. McLachlan DRC, Dam TV, Farnell BJ, Lewis PN (1983) Aluminum inhibition of ADP-ribosylation in vivo and in vitro. Neurobehav Toxicol Teratol 5, 645-647. (Pubitemid 14152001)
157. Lukiw WJ, LeBlanc HJ, Carver LA, McLachlan DR, Bazan NG (1998) Runon gene transcription in human neocortical nuclei. Inhibition by nanomolar aluminum and implica-tions for neurodegenerative disease. J Mol Neurosci 11, 67-78. (Pubitemid 28527381)
158. Cherroret G, Desor D, Hutin MF, Burnel D, Capolaghi B, Lehr PR (1996) Effects of aluminum chloride on normal and uremic adult male rats. Tissue distribution, brain choline acetyltransferase activity, and some biological variables. Biol Trace Elem Res 54, 43-53. (Pubitemid 26274775)
159. King RG (1984) Do raised brain aluminium levels in Alzheimer's dementia contribute to cholinergic neuronal deficits? Med Hypotheses 14, 301-306. (Pubitemid 15183016)
160. King RG, Sharp JA, Boura AL (1983) Aluminium, choline transportation and Alzheimer's disease. Med J Aust 2, 606-607.
161. Huber CT, FriedenE (1970) The inhibition of ferroxidase by trivalent and other metal ions. J Biol Chem 245, 3979-3984.
162. Abdel-Ghany M, el-Sebae AK, Shalloway D (1993) aluminum-induced nonenzymatic phospho-incorporation into human tau and other proteins. J Biol Chem 268, 11976-11981. (Pubitemid 23168159)
163. Banks WA, Kastin AJ (1989) Aluminum-induced neu-rotoxicity: alterations in membrane function at the blood-brain barrier. Neurosci Biobehav Rev 13, 47-53. (Pubitemid 19215169)
164. Nehru B, Anand P (2005) Oxidative damage following chronic aluminium exposure in adult and pup rat brains. J Trace Elem Med Biol 19, 203-208. (Pubitemid 41606717)
165. Jing Y, Wang Z, Song Y (2004) Quantitative study of aluminum-induced changes in synaptic ultrastructure in rats. Synapse 52, 292-298. (Pubitemid 38590809)
166. Bondy SC, Ali SF, Guo-Ross S (1998) Aluminum but not iron treatment induces pro-oxidant events in the rat brain. Mol Chem Neuropathol 34, 219-232. (Pubitemid 29168580)
167. Jope RS, Johnson GV (1992) Neurotoxic effects of dietary aluminium. Ciba Found Symp 169, 254-262; discussion 262-257.
168. Johnson GV, Watson AL Jr, Lartius R, Uemura E, Jope RS (1992) Dietary aluminum selectively decreases MAP-2 in brains of developing and adult rats. Neurotoxicology 13, 463-474.
169. Bowdler NC, Beasley DS, Fritze EC, Goulette AM, Hatton JD, Hession J, Ostman DL, Rugg DJ, Schmittdiel CJ (1979) Behavioral effects of aluminum ingestion on animal and human subjects. Pharmacol Biochem Behav 10, 505-512. (Pubitemid 9182932)
170. Thorne BM, Donohoe T, Lin KN, Lyon S, Medeiros DM, Weaver ML (1986) Aluminum ingestion and behavior in the Long-Evans rat. Physiol Behav 36, 63-67. (Pubitemid 16149813)
171. Pivnick EK, Kerr NC, Kaufman RA, Jones DP, Chesney RW (1995) Rickets secondary to phosphate depletion. A sequela of antacid use in infancy. Clin Pediatr (Phila) 34, 73-78.
172. Fewtrell MS, Bishop NJ, Edmonds CJ, Isaacs EB, Lucas A (2009) Aluminum exposure from parenteral nutrition in preterm infants: bone health at 15-year follow-up. Pediatrics 124, 1372-1379.
173. Candy JM, Oakley AE, Mountfort SA, Taylor GA, Morris CM, Bishop HE, Edwardson JA (1992) The imaging and quantification of aluminium in the human brain using dynamic secondary ion mass spectrometry (SIMS). Biol Cell 74, 109-118.
174. Lukiw WJ, Krishnan B, Wong L, Kruck TP, Bergeron C, Crapper McLachlan DR (1992) Nuclear compartmentaliza-tion of aluminum in Alzheimer's disease (AD). Neurobiol Aging 13, 115-121.
175. Yokel RA, Allen DD, Ackley DC (1999) The distribution of aluminum into and out of the brain. J Inorg Biochem 76, 127-132.
176. Exley C, Burgess E, Day JP, Jeffery EH, Melethil S, Yokel RA (1996) Aluminum toxicokinetics. J Toxicol Environ Health 48, 569-584.
177. French P, Gardner MJ, Gunn M (1989) Dietary aluminium and Alzheimer's disease. Food Chem Toxicol 27, 495-496.
178. Wenk GL, Stemmer KL (1981) The influence of ingested aluminum upon norepinephrine and dopamine levels in the rat brain. Neurotoxicology 2, 347-353. (Pubitemid 12149470)
179. Abreo K (2001) Aluminum-induced bone disease: impli-cations for Alzheimer's disease. In A luminium and Alzheimer's Disease: The science that describes the link, Exley C, ed., Elsevier Science, Amsterdam, pp. 37-59.
180. D'Haese PC, Couttenye MM, De Broe ME (1996) Diagnosis and treatment of aluminium bone disease. Nephrol Dial Transplant 11(Suppl 3), 74-79. (Pubitemid 26278593)
181. Ebersole PS, Hess PA, Luggen AS (2004) Age-related changes: renal changes. In Toward Healthy Aging: Human Needs and Nursing Response, Ledbetter MS, Gower LK, eds, Mosby Inc St Louis, MO, p. 89.
182. Lukiw WJ, Kruck TP, McLachlan DR (1989) Linker histone-DNA complexes: enhanced stability in the pres-ence of aluminum lactate and implications for Alzheimer's disease. FEBS Lett 253, 59-62. (Pubitemid 19212546)
183. McLachlan DRC, Lukiw WJ, Mizzen CA, Kruck TP (1989) Chromatin structure in Alzheimer's disease: effect on 5' leader sequence for NF-L gene and role of aluminum. Prog Clin Biol Res 317, 1061-1075.
184. McLachlan DRC, Lukiw WJ, Kruck TP (1989) New evidence for an active role of aluminum in Alzheimer's disease. Can J Neurol Sci 16, 490-497. (Pubitemid 19278359)
185. McLachlan DRC, Lukiw WJ, Kruck TPA (1990) Aluminum, altered transcription, and the pathogenesis of Alzheimer's disease. Env Geochem Health 12, 103-114.
186. Mann DM (1996) Pyramidal nerve cell loss in Alzheimer's disease. Neurodegeneration 5, 423-427. (Pubitemid 27077904)
187. Heckers S, Geula C, Mesulam MM (1992) Acetylcholin-esterase-rich pyramidal neurons in Alzheimer's disease. Neurobiol Aging 13, 455-460.
188. Salimi I, Friel KM, Martin JH (2008) Pyramidal tract stim-ulation restores normal corticospinal tract connections and visuomotor skill after early postnatal motor cortex activity blockade. J Neurosci 28, 7426-7434.
189. Elston GN (2003) Cortex, cognition and the cell: new insights into the pyramidal neuron and prefrontal function. Cereb Cortex 13, 1124-1138. (Pubitemid 37336435)
190. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P (1995) A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 65, 717-724.
191. Favarato M, Mizzen CA, McLachlan DR (1992) Resolution of serum aluminum-binding proteins by size-exclusion chromatography: identification of a new carrier of aluminum in human serum. J Chromatogr 576, 271-285.
192. Day JP, Barker J, Evans LJA, Perks J, Seabright PJ, Ackrill P, Lilley JS, Drumm PV, Newton GWA (1991) Aluminium absorption studied by 26Al tracer. Lancet 337, 1345.
193. Favarato M, Mizzen C, Kruck TPA (1990) Chromatographic resolution of aluminum binding components in human serum. Neurobiol Aging 11, 315.
194. Beardmore J, Exley C (2009) Towards a model of non-equilibrium binding of metal ions in biological systems. J Inorg Biochem 103, 205-209.
195. Moos T, Morgan EH (2000) Transferrin and transferrin receptor function in brain barrier systems. Cell Mol Neurobiol 20, 77-95. (Pubitemid 30090917)
196. Morris CM, Candy JM, Kerwin JM, Edwardson JA (1994) Transferrin receptors in the normal human hippocampus and in Alzheimer's disease. Neuropathol Appl Neurobiol 20, 473-477. (Pubitemid 24326470)
197. Pardridge WM, Eisenberg J, Yang J (1987) Human blood-brain barrier transferrin receptor. Metabolism 36, 892-895. (Pubitemid 17135085)
198. Sakajiri T, Yamamura T, Kikuchi T, Ichimura K, Sawada T, Yajima H (2009) Absence of binding between the human transferrin receptor and the transferrin complex ofbiological toxic trace element, aluminum, because of an incomplete open/closed form of the complex. Biol Trace Elem Res 136, 279-286.
199. Ha-Duong NT, Hemadi M, Chikh Z, Chahine JM (2008) Kinetics and thermodynamics of metal-loaded transferrins: transferrin receptor 1 interactions. Biochem Soc Trans 36, 1422-1426.
200. Hemadi M, Miquel G, Kahn PH, El Hage Chahine JM (2003) Aluminum exchange between citrate and human serum transferrin and interaction with transferrin receptor 1. Biochemistry 42, 3120-3130. (Pubitemid 36331558)
201. Smans KA, D'Haese PC, Van Landeghem GF, Andries LJ, Lamberts LV, Hendy GN, De Broe ME (2000) Transferrin-mediated uptake of aluminium by human parathyroid cells results in reduced parathyroid hormone secretion. Nephrol Dial Transplant 15, 1328-1336.
202. McGregor SJ, Brock JH, Halls D (1991) The role of transferrin and citrate in cellular uptake of aluminium. Biol Met 4, 173-175.
203. McGregor SJ, Naves ML, Birly AK, Russell NH, Halls D, Junor BJ, Brock JH (1991) Interaction of aluminium and gallium with human lymphocytes: the role of transferrin. Biochim Biophys Acta 1095, 196-200.
204. Abreo K, Jangula J, Jain SK, Sella M, Glass J (1991) aluminum uptake and toxicity in cultured mouse hepatocytes. J Am Soc Nephrol 1, 1299-1304.
205. Fleming J, Joshi JG (1987) Ferritin: isolation of aluminum-ferritin complex from brain. Proc Natl Acad Sci USA 84, 7866-7870.
206. Dedman DJ, Treffry A, Candy JM, Taylor GA, Morris CM, Bloxham CA, Perry RH, Edwardson JA, Harrison PM (1992) Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients. Biochem J 287(Pt 2), 509-514.
207. SpadaPL, Rossi C, Alimonti A, Bocca B, Ricerca BM, Bocci MG, Carvelli M, Vulpio C, Luciani G, De Sole P (2009) Iron, zinc and aluminium ferritin content of hemodialysis hyperferritinemic patients: comparison with other hyperfer-ritinemic clinical conditions and normoferritinemic blood donors. Clin Biochem 42, 1654-1657.
208. Brewer GJ (2007) Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease. Exp Biol Med (Maywood) 232, 323-335. (Pubitemid 46203301)
209. Alexandrov PN, Zhao Y, Pogue AI, Tarr MA, Kruck TP, Percy ME, Cui JG, Lukiw WJ (2005) Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J Alzheimers Dis 8, 117-127; discussion 209-115. (Pubitemid 43227158)
210. Smith MA, Harris PL, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94, 9866-9868. (Pubitemid 27408156)
211. Exley C (2004) The pro-oxidant activity of aluminum. Free Radic Biol Med 36, 380-387. (Pubitemid 38130236)
212. Verstraeten SV, Golub MS, Keen CL, Oteiza PI (1997) Myelin is a preferential target of aluminum-mediated oxida-tive damage. Arch Biochem Biophys 344, 289-294. (Pubitemid 27344064)
213. Khan A, Dobson JP, Exley C (2006) Redox cycling of iron by Abeta42. Free Radic Biol Med 40, 557-569.
214. Floyd RA (1999) Antioxidants, oxidative stress, and degen-erative neurological disorders. Proc Soc Exp Biol Med 222, 236-245. (Pubitemid 129708638)
215. Olanow CW (1993) A radical hypothesis for neurodegener-ation. Trends Neurosci 16, 439-444.
216. Pandya JD, Dave KR, Katyare SS (2004) Effect of long-term aluminum feeding on lipid/phospholipid profiles of rat brain myelin. Lipids Health Dis 3, 13.
217. Sokoloff L (1981) Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed Proc 40, 2311-2316. (Pubitemid 11036104)
218. Maker HS, Clarke DD, Lajtha AL (1972) Intermediary metabolism of carbohydrates and amino acids. In Basic Neurochemistry, Siegal GL, Albers RW, Katzman R, Agranoff BW, eds, Little, Brown and Co., Boston, pp. 279-307.
219. Johnson GV, Jope RS (1986) Aluminum impairs glucose utilization and cholinergic activity in rat brain in vitro. Toxicology 40, 93-102. (Pubitemid 16079879)
220. McLachlan DRC, Dalton AJ (1973) Alterations in short-term retention, conditioned avoidance response acquisition and motivation following aluminum induced neurofibrillary degeneration. Physiol Behav 10, 925-933.
221. Hellwig B (1993) How the myelin picture of the human cerebral cortex can be computed from cytoarchitectural data. A bridge between von Economo and Vogt. J Hirnforsch 34, 387-402. (Pubitemid 23349276)
222. Lintl P, Braak H (1983) Loss of intracortical myelinated fibers: a distinctive age-related alteration in the human striate area. Acta Neuropathol 61, 178-182. (Pubitemid 13015730)
223. Grant P, Pant HC (2000) Neurofilament protein synthesis and phosphorylation. J Neurocytol 29, 843-872. (Pubitemid 32781483)
224. Shea TB, Beermann ML (1994) Respective roles of neurofil-aments, microtubules, MAP1B, and tau in neurite outgrowth and stabilization. Mol Biol Cell 5, 863-875. (Pubitemid 24283767)
225. Jicha GA, Weaver C, Lane E, Vianna C, Kress Y, Rockwood J, Davies P (1999) cAMP-dependent protein kinase phos-phorylations on tau in Alzheimer's disease. J Neurosci 19, 7486-7494. (Pubitemid 29404605)
226. Blanchard BJ, devi Raghunandan R, Roder HM, Ingram VM (1994) Hyperphosphorylation of human TAU by brain kinase PK40erk beyond phosphorylation by cAMP-dependent PKA: relation to Alzheimer's disease. Biochem Biophys Res Commun 200, 187-194.
227. El-Sebae AH, Abdel-Ghany ME, Shalloway D, Abou Zeid MM, Blancato J, Saleh MA (1993) Aluminum interaction with human brain tau protein phosphorylation by various kinases. J Environ Sci Health B 28, 763-777. (Pubitemid 23332402)
228. Markesbery WR (1999) The role of oxidative stress in Alzheimer disease. Arch Neurol 56, 1449-1452.
229. Markesbery WR, Carney JM (1999) Oxidative alterations in Alzheimer's disease. Brain Pathol 9, 133-146. (Pubitemid 29056524)
230. Gomez M, Esparza JL, Nogues MR, Giralt M, Cabre M, Domingo JL (2005) Prooxidant activity of aluminum in the rat hippocampus: gene expression of antioxidant enzymes after melatonin administration. Free Radic Biol Med 38, 104-111. (Pubitemid 39626915)
231. Pratico D, Uryu K, Sung S, Tang S, Trojanowski JQ, Lee VM (2002) Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J16, 1138-1140.
232. Bondy SC, Liu D, Guo-Ross S (1998) Aluminum treatment induces nitric oxide synthase in the rat brain. Neurochem Int 33, 51-54. (Pubitemid 28310715)
233. Pratico D, Rokach J, Lawson J, Fitzgerald GA (2004) F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids 128, 165-171. (Pubitemid 38167385)
234. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, Fitzgerald GA (2000) Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48, 809-812.
235. Pratico D, V MYL, Trojanowski JQ, Rokach J, Fitzgerald GA (1998) Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J12, 1777-1783. (Pubitemid 28553673)
236. Wu J, Du F, Zhang P, Khan IA, Chen J, Liang Y (2005) Thermodynamics of the interaction of aluminum ions with DNA: implications for the biological function of aluminum. J Inorg Biochem 99, 1145-1154. (Pubitemid 40514424)
237. Lukiw WJ, Percy ME, Kruck TP (2005) Nanomolar Aluminum induces pro-inflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J Inorg Biochem 99, 1895-1898. (Pubitemid 41253779)
238. Ripovi D, Platilova V, Strunecka A, Jirak R, Hoschl C (2000) Cytosolic calcium alterations in platelets of patients with early stages of Alzheimer's disease. Neurobiol Aging 21, 729-734.
239. Grammas P, Roher AE, Ball MJ (1994) Increased accu-mulation of cAMP in cerebral microvessels in Alzheimer's disease. Neurobiol Aging 15, 113-116. (Pubitemid 24075019)
240. Young-Pearse TL, Chen AC, Chang R, Marquez C, Selkoe DJ (2008) Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Dev 3, 15.
241. De Strooper B, Annaert W (2000) Proteolyticprocessing and cell biological functions of the amyloid precursor protein. J Cell Sci 113 (Pt 11), 1857-1870. (Pubitemid 30386490)
242. Bell KF, Zheng L, Fahrenholz F, Cuello AC (2008) ADAM-10 over-expression increases cortical synaptogen-esis. Neurobiol Aging 29, 554-565. (Pubitemid 351312818)
243. Alzheimer's Association (alz.org), Alzheimer Myths, http://www.alz.org/ alzheimers-disease-myths-about-alzheimers.asp, Last Updated January 4, 2010, Accessed on August 4, 2010.
244. Alzheimer's Association (alz.org), Association responds to USA TODAY letter to the editor, http://www.alz.org/news-and-events-alzheimer-news-02-02- 2005.asp, Last Updated December 22, 2006, Accessed on August 4, 2010.
245. McLachlan DRC (1995) Aluminium and the risk for alzheimer's disease. Environmetrics 6, 233-275. (Pubitemid 26431415)
246. McLachlan DRC, KruckTP, Lukiw WJ, Krishnan SS (1991) Would decreased aluminum ingestion reduce the incidence of Alzheimer's disease? CMAJ 145, 793-804.
247. Perl DP (2001) The association of aluminum and neu-rofibrillary degeneration in Alzheimer's Disease, a personal perspective. In A luminium and Alzheimer's Disease: The science that describes the link, Exley C, ed., Elsevier Sci-ence, Amsterdam, pp. 133-147.
248. Altmann P (2001) Aluminium induced disease in subjects with and without renal failure-does it help us understand the role of aluminium in Alzheimer's Disease? In Aluminium and Alzheimer's Disease: The Science that Describes the Link, Exley C, ed., Elsevier Science, Amsterdam, pp. 1-37.
249. Golub MS (2001) Behavioral studies in animals: past and potential contribution to the understanding of the relationship between aluminium and Alzheimer's disease. In Aluminium and Alzheimer's Disease: The Science that Describes the Link, Exley C, ed., Elsevier Science, Amsterdam, pp. 169-189.
250. Pendlebury WW, Beal MF, Kowall NW, Solomon PR (1988) Neuropathologic, neurochemical and immunocytochemi-cal characteristics of aluminum-induced neurofilamentous degeneration. Neurotoxicology 9, 503-510.
251. Rozas VV, Port FK, Easterling RE (1978) An outbreak of dialysis dementia due to aluminum in the dialysate. J Dial 2, 459-470. (Pubitemid 9134695)
252. Flendrig JA, Kruis H, Das HA (1976) Aluminium intox-ication: the cause of dialysis dementia? Proc Eur Dial Transplant Assoc 13, 355-368.
253. McLachlan DRC, Tomko GJ (1975) Neuronal correlates of an encephalopathy associated with aluminum neurofibrillary degeneration. Brain Res 97, 253-264.
254. Platt B, Carpenter DO, Busselberg D, Reymann KG, Riedel G (1995) Aluminum impairs hippocampal long-term poten-tiation in rats in vitro and in vivo. Exp Neurol 134, 73-86.
255. Beal MF, Mazurek MF, Ellison DW, Kowall NW, Solomon PR, Pendlebury WW (1989) Neurochemical characteristics of aluminum-induced neurofibrillary degeneration in rabbits. Neuroscience 29, 339-346. (Pubitemid 19113425)
256. Zatta P, Ibn-Lkhayat-Idrissi M, Zambenedetti P, Kilyen M, Kiss T (2002) In vivo and in vitro effects of aluminum on the activity of mouse brain acetylcholinesterase. Brain Res Bull 59, 41-45.
257. Moraes MS, Leite SR (1994) Inhibition of bovine brain acetylcholinesterase by aluminum. Braz J Med Biol Res 27, 2635-2638.
258. Patocka J, Bajgar J (1987) Aluminium activation and inhi-bition of human brain acetylcholinesterase in vitro. Inorg Chim Acta 135, 161-163.
259. Lai JC, Guest JF, Leung TK, Lim L, Davison AN (1980) The effects of cadmium, manganese and aluminium on sodium-potassium-activated and magnesium-activated adenosine triphosphatase activity and choline uptake in rat brain synap-tosomes. Biochem Pharmacol 29, 141-146. (Pubitemid 10202593)
260. Cucarella C, Montoliu C, Hermenegildo C, Saez R, Manzo L, Minana MD, Felipo V (1998) Chronic exposure to Aluminumimpairs neuronal glutamate-nitric oxide-cyclic GMP pathway. J Neurochem 70, 1609-1614. (Pubitemid 28136975)
261. Meiri H, Banin E, Roll M, Rousseau A (1993) Toxic effects of aluminium on nerve cells and synaptic transmission. Prog Neurobiol 40, 89-121.
262. Rao KS (1990) Effects of aluminium salts on synaptosomal enzymes-an in vitro kinetic study. Biochem Int 22, 725-734.
263. Wong PC, Lai JC, Lim L, Davison AN (1981) Selective inhibition of L-glutamate and gammaaminobutyrate trans-port in nerve ending particles by aluminium, manganese, and cadmium chloride. J Inorg Biochem 14, 253-260. (Pubitemid 11063057)
264. Altindag ZZ, Baydar T, Engin AB, Sahin G (2003) Effects of the metals on dihydropteridine reductase activity. Toxicol In Vitro 17, 533-537. (Pubitemid 37352659)
265. Shafer TJ, Nostrandt AC, Tilson HA, Mundy WR (1994) Mechanisms underlying AlCl3 inhibition of agonist-stimulated inositol phosphate accumulation. Role of calcium, G-proteins, phospholipase C and protein kinase C Biochem Pharmacol 47, 1417-1425.
266. Shafer TJ, Mundy WR, Tilson HA (1993) Aluminum decreases muscarinic, adrenergic, and metabotropic receptor-stimulated phosphoinositide hydrolysis in hip-pocampal and cortical slices from rat brain. Brain Res 629, 133-140. (Pubitemid 23328796)
267. Cochran M, Elliott DC, Brennan P, Chawtur V (1990) Inhi-bition of protein kinase C activation by low concentrations of aluminium. Clin ChimActa 194, 167-172.
268. Koenig ML, Jope RS (1987) Aluminum inhibits the fast phase of voltage-dependent calcium influxes into synapto-somes. J Neurochem 49, 316-320. (Pubitemid 17108266)
269. Siegel N, Suhayda C, Haug A (1982) Aluminum changes the conformation of calmodulin. Physiol Chem Phys 14, 165-167.
270. Beal MF, Hyman BT, Koroshetz W (1993) Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 16, 125-131. (Pubitemid 23085467)
271. Drago D, Cavaliere A, Mascetra N, Ciavardelli D, di Ilio C, Zatta P, Sensi SL (2008) Aluminum modulates effects of beta amyloid(1-42) on neuronal calcium homeostasis and mitochondria functioning and is altered in a triple transgenic mouse model of Alzheimer's disease. Rejuvenation Res 11, 861-871.
272. Lipman JJ, ColowickSP, Lawrence PL, Abumrad NN (1988) Aluminum induced encephalopathy in the rat Life Sci 42, 863-875. (Pubitemid 18065328)
273. Li X, Zheng H, Zhang Z, Li M, Huang Z, Schluesener HJ, Li Y, Xu S (2009) Glia activation induced by periph-eral administration of aluminum oxide nanoparticles in rat brains. Nanomed Nanotech Biol Med 5, 473-479.
274. Muma NA, Troncoso JC, Hoffman PN, Koo EH, Price DL (1988) Aluminum neurotoxicity: altered expression of cytoskeletal genes. Brain Res 427, 115-121.
275. McLachlan DRC, Krishnan SS, Quittkat S (1976) Alu-minium, neurofibrillary degeneration and Alzheimer's disease. Brain 99, 67-80.
276. Humphreys WG, Macdonald TL (1988) The effects on tubu-lin polymerization and associated guanosine triphosphate hydrolysis of aluminum ion, fluoride and fluoroaluminate species. Biochem Biophys Res Commun 151, 1025-1032. (Pubitemid 18095223)
277. Shea TB, Beermann ML, Nixon RA (1995) Aluminum treatment of intact neuroblastoma cells alters neurofilament subunit phosphorylation, solubility, and proteolysis. Mol Chem Neuropathol 26, 1-14.
278. Shin RW, Kruck TP, Murayama H, Kitamoto T (2003) A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease. Brain Res 961, 139-146. (Pubitemid 36090130)
279. Shin RW, Lee VM, Trojanowski JQ (1994) Aluminum mod-ifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro. J Neurosci 14, 7221-7233. (Pubitemid 24336392)
280. Yamamoto H, Saitoh Y, Yasugawa S, Miyamoto E (1990) Dephosphorylation of tau factor by protein phosphatase 2A in synaptosomal cytosol fractions, and inhibition by Aluminum. J Neurochem 55, 683-690. (Pubitemid 120021646)
281. Exley C (2006) Aluminium and iron, but neither copper nor zinc, are key to the precipitation of beta-sheets of Abeta-{42} in senile plaque cores in Alzheimer's disease. J Alzheimers Dis 10, 173-177.
282. Exley C, Price NC, Kelly SM, Birchall JD (1993) An inter-action of beta-amyloid with aluminium in vitro. FEBS Lett 324, 293-295.
283. Fasman GD, Perczel A, Moore CD (1995) Solubilization of beta-amyloid-(1-42)-peptide: reversing the beta-sheet con-formation induced by aluminum with silicates. Proc Natl AcadSci USA 92, 369-371.
284. Exley C, Korchazhkina OV (2001) Promotion of formation of amyloid fibrils by aluminium adenosine triphosphate (AlATP). J Inorg Biochem 84, 215-224. (Pubitemid 33733447)
285. Kawahara M, Kato M, Kuroda Y (2001) Effects of aluminum on the neurotoxicity of primary cultured neurons and on the aggregation of beta-amyloid protein. Brain Res Bull 55, 211-217. (Pubitemid 32722161)
286. Drago D, Bettella M, Bolognin S, Cendron L, Scancar J, Milacic R, Ricchelli F, Casini A, Messori L, Tognon G, Zatta P (2008) Potential pathogenic role of beta-amyloid(1-42)-aluminum complex in Alzheimer's disease. Int J Biochem Cell Biol 40, 731-746. (Pubitemid 351288594)
287. Mills J, Laurent Charest D, Lam F, Beyreuther K, Ida N, Pelech SL, Reiner PB (1997) Regulation of amyloid pre-cursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J Neurosci 17, 9415-9422. (Pubitemid 28006386)
288. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stim-ulated by activation of muscarinic acetylcholine receptors. Science 258, 304-307.
289. Xu H, Greengard P, Gandy S (1995) Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor protein. J Biol Chem 270, 23243-23245.
290. Arribas J, Massague J (1995) Transforming growth factor-alpha and beta-amyloid precursor protein share a secretory mechanism. J Cell Biol 128, 433-441.
291. Sakamoto T, Saito H, Ishii K, Takahashi H, Tanabe S, Ogasawara Y (2006) Aluminum inhibits proteolytic degradation of amyloid beta peptide by cathepsin D: a potential link between aluminum accumulation and neuritic plaque deposition. FEBS Lett 580, 6543-6549. (Pubitemid 44827011)
292. Alfrey AC (1986) Dialysis encephalopathy. Kidney Int Suppl 18, S53-S57.
293. Alfrey AC (1978) Dialysis encephalopathy syndrome. Annu Rev Med 29, 93-98.
294. Alfrey AC, LeGendre GR, Kaehny WD (1976) The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294, 184-188.
295. Wisniewski HM, Sturman JA, Shek JW (1982) Chronic model of neurofibrillary changes induced in mature rabbits by metallic aluminum. Neurobiol Aging 3, 11-22. (Pubitemid 12066361)
296. Petit TL, Biederman GB, McMullen PA (1980) Neu-rofibrillary degeneration, dendritic dying back, and learning-memory deficits after aluminum administration: implications for brain aging. Exp Neurol 67, 152-162. (Pubitemid 10172200)
297. McLachlan DC (1973) Experimental neurofibrillary degeneration and altered electrical activity. Electroencephalogr Clin Neurophysiol 35, 575-588.
298. Klatzo I, Wisniewski H, Streicher E (1965) Experimental production of neurofibrillary degeneration. I. Light microscopic observations. J Neuropathol Exp Neurol 24, 187-199.
299. Shigematsu K, McGeer PL (1992) Accumulation of amy-loid precursor protein in damaged neuronal processes and microglia following intracerebral administration of Aluminum salts. Brain Res 593, 117-123.
300. Hewitt CD, Herman MM, Lopes MB, Savory J, Wills MR (1991) Aluminium maltol-induced neurocytoskeletal changes in fetal rabbit midbrain in matrix culture. Neuropathol Appl Neurobiol 17, 47-60.
301. Wisniewski H, Narkiewicz O, Wisniewska K (1967) Topography and dynamics of neurofibrillar degeneration in aluminum encephalopathy. Acta Neuropathol 9, 127-133.
302. Savory J, Huang Y, Wills MR, Herman MM (1998) Rever-sal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease. Neurotoxicology 19, 209-214. (Pubitemid 28150971)
303. Selkoe DJ, Liem RK, Yen SH, Shelanski ML (1979) Biochemical and immunological characterization of neu-rofilaments in experimental neurofibrillary degeneration induced by aluminum. Brain Res 163, 235-252. (Pubitemid 9138622)
304. Gambetti P, Autilio-Gambetti L, Perry G, Shecket G, Crane RC (1983) Antibodies to neurofibrillary tangles of Alzheimer's disease raised from human and animal neuro-filament fractions. Lab Invest 49, 430-435. (Pubitemid 13021735)
305. Walton JR (2007) An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovac-uolar degeneration. J Inorg Biochem 101, 1275-1284. (Pubitemid 47313520)
306. Exley C, Esiri MM (2006) Severe cerebral congophilic angiopathy coincident with increased brain aluminium in a resident of Camelford, Cornwall, UK. J Neurol Neurosurg Psychiatry 77, 877-879. (Pubitemid 44023186)
307. Yumoto S, Kakimi S, Ohsaki A, Ishikawa A (2009) Demon-stration of aluminum in amyloid fibers in the cores of senile plaques in the brains of patients with Alzheimer's disease. J Inorg Biochem 103, 1579-1584.
308. Walton JR, Diamond TH, Kumar S, Murrell GA (2007) A sensitive stain for aluminum in undecalcified cancellous bone. J Inorg Biochem 101, 1285-1290. (Pubitemid 47313524)
309. Kruck TP, Cui JG, Percy ME, Lukiw WJ (2004) Molecu-lar shuttle chelation: the use of ascorbate, desferrioxamine and Feralex-G in combination to remove nuclear bound Aluminum. Cell Mol Neurobiol 24, 443-459. (Pubitemid 38988074)
310. Bertholf RL, Roman JM, Brown S, Savory J, Wills MR (1984) Aluminum hydroxide-induced osteomalacia, encephalopathy, and hyperaluminemia in CAPD. Treatment with desfenioxamine. Perit Dial Int 4, 30-32. (Pubitemid 14133266)
311. Williams P, Khanna R, Crapper McLachlan DR (1981) Enhancement of aluminum removal by desfemoxamine in a patient on continuous ambulatory peritoneal dialysis with dementia. Perit Dial Int 1, 73.
312. Flarend R (2001) Absorption of aluminum from antiperspi-rants and vaccine adjuvants. In Aluminium and Alzheimer's Disease: The Science that Describes the Link, Exley C, ed., Elsevier Science, Amsterdam, pp. 75-97.
313. Flarend R, Bin T, Elmore D, Hem SL (2001) A prelim-inary study of the dermal absorption of aluminium from antiperspirants using aluminium-26. Food Chem Toxicol 39, 163-168. (Pubitemid 32239355)
314. Autret-Leca E, Bensouda-Grimaldi L, Jonville-Bera AP, Beau-Salinas F (2006) Pharmacovigilance of vaccines. Arch Pediatrie 13, 175-180. (Pubitemid 43187917)
315. Koo WW, Kaplan LA, Krug-Wispe SK (1988) Aluminum contamination of infant formulas. J Parenter Enteral Nutr 12, 170-173.
316. CDC, Recommended Immunization Schedule for Per-sons Aged 0 Through 6 Years, United States 2010, http://www.cdc.gov/vaccines/recs/schedules/default. htm, Last updated June 15 2010, Accessed on August 4, 2010.
317. Srinivasan PT, Viraraghavan T, Subramanian KS (1999) Aluminiumin drinking water: an overview. Water S.A. 25, 47-55.